MGRX vs PFE vs JNJ vs HIMS

For growth investors, Hims & Hers Health, Inc.

(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -15. 8% for Mangoceuticals, Inc. (MGRX). Pfizer Inc. (PFE) offers the better valuation at 19. 5x trailing P/E (8. 9x forward), making it the more compelling value choice. Analysts rate Johnson & Johnson (JNJ) a "Buy" — based on 40 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Pfizer Inc.

(PFE) is the cheapest at 19. 5x versus Hims & Hers Health, Inc. at 50. 3x. On forward P/E, Pfizer Inc. is actually cheaper at 8. 9x.

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +137. 6%, compared to -99. 4% for Mangoceuticals, Inc. (MGRX). Over 10 years, the gap is even starker: HIMS returned +161. 9% versus MGRX's -99. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Johnson & Johnson (JNJ) is the lower-risk stock at 0.

06β versus Hims & Hers Health, Inc. 's 2. 40β — meaning HIMS is approximately 4114% more volatile than JNJ relative to the S&P 500. On balance sheet safety, Mangoceuticals, Inc. (MGRX) carries a lower debt/equity ratio of 2% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Hims & Hers Health, Inc.

(HIMS) is pulling ahead at 59. 0% versus -15. 8% for Mangoceuticals, Inc. (MGRX). On earnings-per-share growth, the picture is similar: Mangoceuticals, Inc. grew EPS 48. 7% year-over-year, compared to -57. 8% for Johnson & Johnson. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Johnson & Johnson (JNJ) is the more profitable company, earning 15.

8% net margin versus -1413. 6% for Mangoceuticals, Inc. — meaning it keeps 15. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JNJ leads at 24. 9% versus -1294. 4% for MGRX. At the gross margin level — before operating expenses — PFE leads at 70. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Pfizer Inc.

(PFE) trades at 8. 9x forward P/E versus 51. 5x for Hims & Hers Health, Inc. — 42. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HIMS: 15. 6% to $29. 67.

In this comparison, MGRX (100.

0% yield), PFE (6. 5% yield), JNJ (2. 2% yield) pay a dividend. HIMS does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Johnson & Johnson (JNJ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

06), 2. 2% yield, +132. 3% 10Y return). Hims & Hers Health, Inc. (HIMS) carries a higher beta of 2. 40 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JNJ: +132. 3%, HIMS: +161. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: MGRX is a small-cap income-oriented stock; PFE is a mid-cap income-oriented stock; JNJ is a large-cap quality compounder stock; HIMS is a small-cap high-growth stock. MGRX, PFE, JNJ pay a dividend while HIMS does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.